Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcutis Biotherapeutics, Inc.

https://arcutis.com/

Latest From Arcutis Biotherapeutics, Inc.

Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD

Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.

Business Strategies Clinical Trials

Leo Pharma Strengthens Dermatology Position With Second Eczema Win

The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.

Clinical Trials Business Strategies

China's Connect Eyes Partnerships To Globalize Dermatitis Biologic

Watch out Sanofi. US- and China-based Connect BioPharma is looking to position its novel biologic for atopic dermatitis to compete head-on with best-selling Dupixent both inside and outside China in an increasingly crowded space, says co-founder and CEO Wei Zheng in an exclusive interview with Scrip.

China Commercial

Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis

Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Other Names / Subsidiaries
    • Ducentis BioTherapeutics Ltd
UsernamePublicRestriction

Register